ELI LILLY WILL SOON RELEASE KEY DATA ON ITS WEIGHT LOSS PILL. HERE'S WHY IT COULD BE A GAME-CHANGER

Summary from the TLDR newsletter

Eli Lilly expects to unveil data from several late-stage clinical trials on its experimental once-daily obesity pill this year. Orforglipron is predicted to be as effective, safe, and tolerable to take as semaglutide. The pill targets GLP-1 to suppress appetite and regulate blood sugar. It is unclear whether the pill will have a hefty price similar to current GLP-1 injections, which cost roughly $1,000 per month. The pill could receive US regulatory approval as soon as early 2026.